Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
January 31, 2019
Inspire Medical Systems, Inc. Announces a Positive Coverage Policy Issued by Blue Cross Blue Shield of North Carolina
MINNEAPOLIS, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative ...
January 30, 2019
AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer’s Disease
LAUSANNE, Switzerland, Jan. 30, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU) announced today that Roche, the parent company of its collaboration partner, is discontinuing ...
January 30, 2019
Orphazyme reports positive results from full data set of Phase II/III arimoclomol trial in Niemann-Pick disease Type C (NPC)
Copenhagen, January 30, 2019 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced the full data set ...
January 30, 2019
BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma
LUND, Sweden, Jan. 30, 2019  /PRNewswire/ -- BioInvent International AB (OMXS:BINV) announces today that the U.S. Food and Drug Administration (FDA) has granted the Company ...
January 30, 2019
Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis
NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its ...
January 30, 2019
Kamada Appoints Senior Biopharmaceutical Executive Michal Ayalon, Ph.D., as Vice President of Research and Development
REHOVOT, Israel, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, announced today the appointment of Michal ...
January 30, 2019
Neovasc Announces Renewal of German NUB Status 1 Designation for Neovasc Reducer™ Procedure for Treatment of Refractory Angina
VANCOUVER , Jan. 30, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve ...
January 30, 2019
Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials
Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today provided ...
January 30, 2019
Cormedix Inc. Announces Topline Analysis of the Full Data Set of Phase 3 Lock-It-100 Study Reinforces the Interim Results
BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 30, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
January 30, 2019
aTyr Pharma Announces Research Collaboration with the University of Nebraska Medical Center and Expansion of Successful Pilot Study
SAN DIEGO, Jan. 30, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based ...
January 29, 2019
INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announced today that the US Food and Drug Administration (FDA) has granted Fast Track ...
January 29, 2019
Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis
Sophia Antipolis, France -- Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the U.S. Food and Drug Administration (FDA) has completed ...
January 29, 2019
4D Pharma Announces Publication of Data Highlighting Immuno-Stimulatory Properties of MRx0518
LEEDS, England, January 29, 2019 /PRNewswire/ -- 4D pharma plc (DDDD.L), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the publication of a ...
January 29, 2019
OncoCyte Announces Successful Results of DetermaVu™ R&D Validation Study
ALAMEDA, Calif., Jan. 29, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, ...
January 29, 2019
Neovasc Receives Approval to Proceed with Phase 2 of TIARA-II Study from Clinical Regulators in Germany and the UK
VANCOUVER , Jan 29, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement ...
January 29, 2019
BrainsWay Receives PMDA Approval in Japan of Deep Transcranial Magnetic Stimulation System for Treatment of Major Depressive Disorder
JERUSALEM, Jan. 29, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (BRIN.TA), a global leader in the advanced non-invasive treatment of brain disorders, today announced that its ...
January 29, 2019
Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism
REDWOOD CITY, Calif., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell ...
January 29, 2019
Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress™ in Vienna, Austria
GAITHERSBURG, Md., Jan. 29, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1 ...
January 29, 2019
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation ...
January 29, 2019
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
Daix (France), January 29th, 2019 - Inventiva S.A. ("Inventiva"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis ("NASH"), systemic sclerosis and mucopolysaccharidosis ("MPS"), today ...
Page 48 of 169